Shares of Tocagen Inc. were plummeting on Thursday, falling over 80% to a new record low as the company announced a late-stage trial of its brain cancer treatment did not meet the primary endpoint. The gene company said the study failed to meet its primary endpoint of survival compared with standard of care treatment. Tocagen … Continue reading “Tocagen Inc. Falls Over 80% After Late-stage Trial Fails to Meet Endpoint”
